Company / Accounts Receivable
Bristol Myers Squibb Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$9.6B
FY2025
5-year range
$8.0B / $9.6B
FY2021-FY2025
Trend
+6.4%
vs FY2024
Sector context
#6 of 113
Health Care
What the data says
Among 113 Health Care companies, Bristol Myers Squibb is in the top 5% for accounts receivable. Accounts Receivable has increased for 9 consecutive years, from $3.8B in FY2016 to $9.6B in FY2025.
Based on SEC 10-K filings.
$9.6B in FY2025 with a 5-year CAGR of +5.8%. Top quartile in the Health Care sector.
Improved from $8.9B to $9.6B over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +5.6%
- 5-Year CAGR
- +5.8%
- 10-Year CAGR
- -
Sector benchmark
Top 5% in Health CareTop 5% of 113This company $9.6B Sector average $1.1B
▼
+743.3% above sector average
Key checks
Key Insights
- Bristol Myers Squibb's accounts receivable has grown for 9 consecutive years.
- 5-year CAGR of +5.8%, indicating consistent growth.
- In FY2025, accounts receivable increased 6.4% year-over-year.
- Ranks #6 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.6B | +6.4% |
| FY2024 | $9.0B | +1.5% |
| FY2023 | $8.9B | +9.0% |
| FY2022 | $8.2B | +2.2% |
| FY2021 | $8.0B | +10.5% |
| FY2020 | $7.2B | +11.5% |
| FY2019 | $6.5B | +39.7% |
| FY2018 | $4.6B | +6.6% |
| FY2017 | $4.3B | +15.2% |
| FY2016 | $3.8B | +28.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026